CHAI has developed a database to help suppliers better navigate market opportunities for human papillomavirus, pneumococcal conjugate, rotavirus, and inactivated polio vaccines in middle-income countries (MICs).
There are currently 78 MICs that have never received or have transitioned out of Gavi, the Vaccine Alliance support. These MICs, which collectively have a birth cohort of nearly 50 million children, represent a significant commercial opportunity, for developing country vaccine manufacturers (DCVM). However, effectively selling to these countries will require a different commercial strategy than selling to Gavi-supported countries.
One of the challenges for suppliers is understanding where the MIC commercial opportunities are and which countries to prioritize. Country intelligence on preferences, program readiness, and procurement channels is less readily available compared to Gavi-supported countries, where greater partner presence and a pooled procurement mechanism make doing business easier and often, less costly.
To help address this challenge and create a more competitive vaccine supplier landscape, CHAI has developed a database to help suppliers analyze human papillomavirus, pneumococcal conjugate, rotavirus, and inactivated polio vaccine market opportunities in MICs. The database helps suppliers to develop a tailored go-to-market strategy to inform marketing, tendering, and stakeholder engagement activities.
For further questions about the information provided here, or for more inquiries about how CHAI is working with global partners and suppliers to improve market opportunities in MICs, please reach out to Senior Associate, Vaccines Markets, Jason Zhu at jzhu@clintonhealthaccess.org or Technical Advisor, Vaccines Markets, Khanyisa Mtombeni at kmtombeni@clintonhealthaccess.org.
Author: CHAI
Last updated: February 14, 2022
